This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 06
  • /
  • Shire merger with Baxalta completed.
Industry news

Shire merger with Baxalta completed.

Read time: 1 mins
Last updated:4th Jun 2016
Published:4th Jun 2016
Source: Pharmawand
Shire plc completed its previously announced combination with Baxalta Incorporated creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. Through the combination, Shire expects to deliver double-digit compound annual top-line growth, with over $20 billion in annual projected revenue by 2020 and approximately 65% of total annual revenues being immediately generated by its rare disease products. Shire now has more than 50 programs in clinical development, with a balanced mix of early, mid and late-stage projects. With over 22,000 employees across more than 100 countries, Shire�s expanded global reach and best-in-class products offer the potential to help even more patients around the world with significant unmet needs. Baxalta became an indirect wholly-owned subsidiary of Shire.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights